News Center
2021
- Categories:Milestones
- Author:
- Origin:
- Time of issue:2022-04-22 14:54
- Views:
(Summary description)The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
2021
(Summary description)The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
- Categories:Milestones
- Author:
- Origin:
- Time of issue:2022-04-22 14:54
- Views:
The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
SAUNDERS
WRITE A MESSAGE TO US
Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China Tel： 0756-8135888
©2021 Livzon 京ICP证000000号 Support：300.cn
Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China
©2021 Livzon 京ICP证000000号
Support：300.cn